Scynexis (SCYX) Short term Debt (2013 - 2023)

Scynexis (SCYX) posted Short term Debt of $34.6 million for Q1 2023, up 371.47% on a QoQ basis from $7.3 million in Q3 2018.

Scynexis (SCYX) Short term Debt (2013 - 2023) Analysis & Trends

Scynexis' Short term Debt history runs 5 years deep, the most recent figure standing at $34.6 million for Q1 2023.

Quarterly Short term Debt changed N/A year-over-year to $34.6 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $34.6 million (changed N/A YoY) and the FY2017 annual result came in at $4.3 million, changed N/A from the prior year.
Short term Debt was $34.6 million for Q1 2023 at Scynexis, up from $7.3 million in the prior quarter.
Across five years, Short term Debt topped out at $34.6 million in Q1 2023 and bottomed at $34.6 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Scynexis	21.55 Mn	-15.20 Mn	-

Download Data